Author Topic: (Abst.) Anti-inflammatory DMT and short-term disability progression in SPMS  (Read 128 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9670
  • MS diagnosed 1980
  • Location: Pacific Northwest
The evidence here is Class IV, which is the lowest level of evidence, but the article appeared in Neurology and has a vast number of contributors and collaborators. Also, it's a topic that hasn't often been discussed--what effect DMDs have on people with SPMS.

From PubMed, August 11, 2017:

Neurology. 2017 Aug 9. pii: 10.1212/WNL.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Collaborators (35)

Hupperts R, Bolaños RF, Rio ME, CabreraGomez JA, Verheul F, Slee M, McCombe P, Olascoaga J, Saladino ML, Amato MP, Alroughani R, Cristiano E, Deri N, Sánchez Menoyo JL, Hodgkinson S, Flechter S, Moore F, Petersen T, Ampapa R, Gray O, Skibina O, Csepan T, Singhal B, Braber-Moerland LD, Sirbu CA, Vucic S, Arruda WO, Prévost J, Kasa K, Kermode A, Barnett MH, Shuey N, Imre P, Daskalovska V, Vella N.


To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS).


Using MSBase, an international cohort study, we previously validated a highly accurate definition of SPMS. Here, we identified patients in MSBase who were either untreated or treated with a disease-modifying drug when meeting this definition. Propensity score matching was used to select subpopulations with comparable baseline characteristics. Disability outcomes were compared in paired, pairwise-censored analyses adjusted for treatment persistence, visit density, and relapse rates.


Of the 2,381 included patients, 1,378 patients were matchable (treated n = 689, untreated n = 689). Median pairwise-censored follow-up was 2.1 years (quartiles 1.2-3.8 years).

 No difference in the risk of 6-month sustained disability progression was observed between the groups (HR or hazard ratio 0.9, 95% confidence interval [CI] 0.7-1.1, p = 0.27). We also did not find differences in any of the secondary endpoints: risk of reaching Expanded Disability Status Scale (EDSS) score ≥7 (HR 0.6, 95% CI 0.4-1.1, p = 0.10), sustained disability reduction (HR 1.0, 95% CI 0.8-1.3, p = 0.79), or change in disability burden (area under the EDSS-time curve, β = -0.05, p = 0.09).

Secondary and sensitivity analyses confirmed the results.


Our pooled analysis of the currently available disease-modifying agents used after conversion to SPMS suggests that, on average, these therapies have no substantial effect on relapse-unrelated disability outcomes measured by the EDSS up to 4 years.


This study provides Class IV evidence that for patients with SPMS, disease-modifying treatment has no beneficial effect on short-term disability progression.

The abstract can be seen here.
« Last Edit: August 12, 2017, 02:13:37 pm by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post March 23, 2016, 03:35:11 pm
by agate
0 Replies
Last post September 18, 2016, 10:53:12 am
by agate
0 Replies
Last post February 01, 2019, 09:34:22 pm
by agate
0 Replies
Last post March 13, 2019, 02:56:48 pm
by agate
0 Replies
Last post June 08, 2019, 09:32:13 am
by agate